International Clinical Trial: A single-arm, single-center phase II clinical study of luconosatuzumab combined with toripalimab in the treatment of advanced gastric cancer or gastroesophageal junction cancer that failed first-line immunotherapy

Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122518) titled 'A single-arm, single-center phase II clinical study of luconosatuzumab combined with toripalimab in the treatment of advanced gastric cancer or gastroesophageal junction cancer that failed first-line immunotherapy' on April 14.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Huadong Hospital Affiliated to Fudan University

Condition: Stomach cancer or cancer of the gastroesophageal junction

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026-04-14

Target Sample Size: Test group:33;

Countries of Recruitment: China

To know more, visit https://www.chic...